Thursday 16 October, 2025
Objectives: Tumour necrosis factor alpha (TNFα) is a pro-inflammatory cytokine acting as a promising target for treatment against immune-mediated diseases…
Read moreAbstracts
Impact of covariate model selection methods on covariate effects and their uncertainty in population pharmacokinetic analysis
Thursday 16 October, 2025
Introduction: Covariate analysis is a key step for drug development as it allows, notably, to adjust the dose in subpopulations…
Read moreModel-based bioequivalence approach: robustness to model misspecification for sparse pharmacokinetic bioequivalence studies
Thursday 16 October, 2025
Introduction: Pharmacokinetic (PK) bioequivalence (BE) studies compare a reference (R) to a test (T) treatment in terms of exposure, i.e.,…
Read moreExtension of the covariate clinical relevance determination in population pharmacokinetic analyses to the Least Absolute Shrinkage and Selection Operator (LASSO) and to Genetic Algorithm (GA) approaches
Thursday 16 October, 2025
Introduction: Identifying covariate clinical relevance (CCR) is essential for patient dose adjustment and is a key step according to health…
Read moreA generative and causal pharmacokinetic model for haemophilia A: towards an unified model for all factor VIII concentrates.
Thursday 16 October, 2025
Objectives: Several population pharmacokinetic (PK) models have been developed for the wide range of recombinant factor VIII (rFVIII) concentrates used…
Read moreA Bayesian Optimization Procedure for the Automated Determination of Optimal Limited Sampling Strategies
Thursday 16 October, 2025
Introduction: Pharmacokinetic (PK) guided dosing is a common approach for personalising prophylactic treatment of haemophilia A patients receiving standard or…
Read moreThe Neural Mixed Effects algorithm: leveraging machine learning for pharmacokinetic modelling
Thursday 16 October, 2025
Objectives: There is much interest in the application of machine learning (ML) algorithms for the personalisation of treatment. Nonlinear mixed-effects…
Read moreTime-dependent random effects.
Thursday 16 October, 2025
Introduction In mixed-effect models, random effects are used to explain residual inter-individual variability. Their effect is constant over time, and…
Read moreInvestigating Components of Residual Unexplained Variability in Nonlinear Mixed-Effect Modeling
Thursday 16 October, 2025
Objectives: In nonlinear mixed-effects (NLME) modeling of pharmacokinetic (PK) and pharmacodynamic (PD) data, we refer to two levels of random effects:…
Read moreReuse of a published model to support compassionate use of novel drug formulation for a rare disorder
Thursday 16 October, 2025
Objectives: Drug development for rare disorders has complexities beyond those seen with common diseases. With fewer subjects available for clinical trials,…
Read more